<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4904">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01961102</url>
  </required_header>
  <id_info>
    <org_study_id>BHS-Gyn1</org_study_id>
    <nct_id>NCT01961102</nct_id>
  </id_info>
  <brief_title>OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer</brief_title>
  <official_title>Pilot-study of OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Barmherzige Schwestern Linz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Barmherzige Schwestern Linz</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is to be achieved that in postmenopausal women through the combination of Hysteroscopy
      and intraoperative rapid section a positive predictive value (PPV) regarding the objective
      illness like endometrial cancer or adenomatous hyperplasia of 100% so as a negative
      predictive value (NPV) of 99%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If a patient fulfills the inclusion criteria, the surgeon decides intraoperatively due to
      the aspect in the hysteroscopy if it is a clearly benign result or if it looks suspicious or
      malign.

      In case of a hysteroscopical benign result the patient will be informed about the result
      after the operation.

      In case of a hysteroscopal suspicious or malignant aspect, the curettement will be sent for
      a rapid section. If the hysteroscopic result confirms the hysteroscopic suspicion the
      patient will be informed after the operation and the further treatment can be planned right
      away.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only</study_design>
  <primary_outcome>
    <measure>A negative predictive value of 99 %</measure>
    <time_frame>Intraoperative</time_frame>
    <safety_issue>No</safety_issue>
    <description>To get in combination of hysteroscopy and rapid section of the endometrial curettement a negative predictive value of 99% as well as a positive predictive value of 100%.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Atypical Hyperplasia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hysteroscopy/curettage in case of suspicious aspect will be done a rapid section</intervention_name>
    <other_name>OSCAR Endo Study</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Postmenopausal women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal status (more than 1 year of last menopausal bleeding)

          -  Postmenopausal vaginal bleeding

          -  Asymptomatic postmenopausal endometrial hyperplasia

          -  Understanding of the german language

          -  Signature and consent of the patient

        Exclusion Criteria:

          -  Not able to understand and participate in the study

          -  Premenopausal status

          -  no informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lukas Hefler, Univ.-Doz.</last_name>
    <phone>0043 732 7677</phone>
    <phone_ext>7160</phone_ext>
    <email>lukas.hefler@bhs.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gynaecology, Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postmenopausal bleeding</keyword>
  <keyword>postmenopausal hyperplasia</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>atypical hyperplasia</keyword>
  <keyword>curettage</keyword>
  <keyword>intraoperative rapid section</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
